Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib in Pretreated RET-rearranged Advanced NSCLC
NCT03445000Phase 2Terminated
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Started Nov 2018; status: terminated.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03445000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445000.